Product nameAnti-ErbB 3 (phospho Y1289) antibody [EPNCIR124]
See all ErbB 3 primary antibodies
DescriptionRabbit monoclonal [EPNCIR124] to ErbB 3 (phospho Y1289)
Specificityab133433 only detects ErbB3 phosphorylated at Tyrosine 1289.
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic phosphopeptide corresponding to a region surrounding Tyrosine 1289 of Mouse ErbB3.
- Lysate of MCF7 cells treated with neuregulin.
This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institutes Center for Cancer Research and the lab of Terry Van Dyke. View antibodies from NCI Center for Cancer Research Collaboration.
A trial size is available to purchase for this antibody.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab133443 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 185 kDa (predicted molecular weight: 148 kDa).|
FunctionBinds and is activated by neuregulins and NTAK.
Tissue specificityEpithelial tissues and brain.
Involvement in diseaseDefects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
Developmental stageOverexpressed in a subset of human mammary tumors.
DomainThe cytoplasmic part of the receptor may interact with the SH2 or SH3 domains of many signal-transducing proteins.
modificationsLigand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- c erbB 3 antibody
- c erbB3 antibody
- Erb b2 receptor tyrosine kinase 3 antibody
All lanes : Anti-ErbB 3 (phospho Y1289) antibody [EPNCIR124] (ab133443) at 1/10000 dilution
Lane 1 : MCF7 cell lysate
Lane 2 : MCF7 cell lysate treated with neuregulin
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP conjugated antibody at 1/10000 dilution
Predicted band size: 148 kDa
Observed band size: 185 kDa why is the actual band size different from the predicted?
ab133443 has not yet been referenced specifically in any publications.